Tscan Therapeutics is trading at $0.32, down 8.68% in pre-market, with no clear catalyst identified.
- No fresh company-specific announcement or filing dated September 23, 2026, was identified; the latest major update was the September 2 strategic reorganization.
- Pre-market volume was reported at 7,540 shares, while the biotechnology sector was strong.
- Earlier workforce cuts, a shift to in vivo solid-tumor therapies, and paused Phase 3 ALLOHA-2 enrollment are stale and do not clearly explain the move.